Welcome to our dedicated page for Y-Mabs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (YMAB) generates news that spans commercial oncology performance, clinical development milestones in radioimmunotherapy, and significant corporate transactions. Company announcements consistently describe Y-mAbs as a commercial-stage biopharmaceutical company focused on novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, with its lead commercial asset DANYELZA® (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma.
News coverage for Y-mAbs frequently highlights financial results and segment updates, including quarterly revenue from DANYELZA, ex-U.S. distribution trends, and the allocation of resources between the DANYELZA and Radiopharmaceuticals business units. Earnings releases often discuss cost of goods sold, research and development spending, selling, general, and administrative expenses, and net loss, along with management commentary on operating strategy and capital efficiency.
Another major category of YMAB news involves clinical and R&D developments in the company’s SADA Pretargeted Radioimmunotherapy (PRIT) platform. Press releases describe progress in the GD2-SADA Phase 1 Trial 1001 in GD2-expressing solid tumors, including pharmacokinetic and dosimetry data, and the initiation of the CD38-SADA Phase 1 Trial 1201 in relapsed or refractory non-Hodgkin lymphoma. Y-mAbs also reports on preclinical pharmacokinetic modeling, optimization of radiohaptens such as “Proteus,” and expansion of its radiopharmaceutical pipeline into additional oncology franchises.
Y-mAbs news also covers regulatory and guideline recognition, such as the inclusion of naxitamab-gqgk (DANYELZA) as a Category 2A treatment option in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma. These updates provide context on how DANYELZA is positioned within clinical practice for high-risk neuroblastoma.
A key theme in recent YMAB headlines is corporate transformation and acquisition activity. In August 2025, Y-mAbs announced that SERB Pharmaceuticals, through an affiliate, agreed to acquire the company in an all-cash transaction at $8.60 per share, with an equity value of approximately $412 million, as described in joint press releases and Form 8-K filings. Subsequent news and SEC filings report the commencement and completion of the tender offer, the closing of the merger, and the resulting delisting of Y-mAbs common stock from the Nasdaq Global Select Market.
Investors and observers following YMAB-related news can expect updates on quarterly financial performance, DANYELZA commercial metrics, clinical trial progress for SADA-based programs, radiopharmaceutical R&D strategy, and the implications of the company’s acquisition by an affiliate of SERB Pharmaceuticals. This news flow provides insight into both the historical public-company phase of Y-mAbs and its transition into a privately held subsidiary within a larger specialty pharmaceutical group.
Y-mAbs Therapeutics reported a net revenue of $10.8 million for Q2 2022, a slight decrease of 1% year-over-year, while YTD revenue was $21.3 million, reflecting a 30% increase. DANYELZA® sales rose 42% YTD to $20.3 million. The company has a strong cash position of $133.7 million, expected to fund operations through mid-2024. The FDA has accepted their BLA for omburtamab with a PDUFA date set for November 2022. Management reiterated financial guidance, aiming for DANYELZA revenues between $45-$50 million for the full year.
Y-mAbs Therapeutics (Nasdaq: YMAB) will announce its financial results for Q2 2022 on August 8, 2022, post-market. A conference call will follow on August 9, 2022, at 9 a.m. ET, featuring key executives including Chairman and Interim CEO Thomas Gad. Y-mAbs aims to advance antibody-based cancer therapies, with one FDA-approved product, DANYELZA®, and another candidate, omburtamab, nearing registration. The firm emphasizes its innovative approaches alongside potential risks inherent in drug development and market acceptance.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) announced the initiation of a Phase 1 clinical trial utilizing the GD2-SADA construct to treat malignant melanoma, sarcoma, and small cell lung cancer. The trial, which will enroll approximately 59 patients across 6-10 U.S. sites, consists of three parts focusing on dose optimization and safety. The SADA technology, licensed from MSK and MIT, aims to enhance targeted cancer treatment while minimizing harm to normal tissues. The FDA has accepted the IND for GD2-SADA, marking a significant milestone in Y-mAbs' clinical development strategy.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) announced that the FDA has accepted the Biologics License Application for OMBLASTYS® (omburtamab) to treat pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma for priority review. The FDA set an action date of November 30, 2022, and plans an advisory committee meeting in October 2022. CEO Thomas Gad highlighted that this approval could address a significant unmet medical need and potentially add a second rare disease product to Y-mAbs' portfolio, without significant infrastructure investment.
Y-mAbs Therapeutics announced that Dr. Shakeel Modak will present results from a trial of naxitamab-based chemoimmunotherapy for high-risk neuroblastoma at the ASCO Annual Meeting from June 3-7, 2022. The trial focused on patients with chemoresistant disease, showing a 30.6% objective response rate in the MSK phase 2 trial, with significant responses in heavily pre-treated patients. The treatment showed manageable toxicity, with no unexpected severe side effects. Y-mAbs is advancing its antibody-based therapeutics in cancer treatment.
Y-mAbs Therapeutics reported a 9% sequential revenue increase to $10.5 million for Q1 2022, driven by DANYELZA® sales. The Company anticipates full-year DANYELZA revenues between $45 million and $50 million. Y-mAbs maintains a solid cash position with $156.7 million as of March 31, 2022, expected to fund operations through mid-2024. However, the Company posted a net loss of $28.1 million for the quarter, a decline from net income of $33.4 million in Q1 2021, primarily due to a one-time gain from a prior sale.
Y-mAbs Therapeutics announced it will report its financial results for Q1 2022 on May 9, 2022, after U.S. market close. A conference call is scheduled for May 10, 2022, at 9 a.m. ET with executives including Thomas Gad, Bo Kruse, and Sue Smith. The company is involved in developing antibody-based cancer therapies, with one FDA-approved product, DANYELZA®, and another candidate, omburtamab, in the registration stage. For more information, investors can join the conference call using specific access numbers and a provided webcast link.
Y-mAbs Therapeutics announces significant management changes, with Dr. Claus Moller stepping down as CEO and Board Member. Thomas Gad, the Founder and Chairman, assumes the role of Interim CEO while Dr. Jim Healy is appointed as Chairman. The company reported first-quarter 2022 revenues of $10.5 million, a 9% increase sequentially, and provided revenue guidance of $45-$50 million for the year. As of March 31, 2022, Y-mAbs has $156.7 million in cash, ensuring funding until mid-2024, amidst ongoing regulatory review of their product omburtamab.
Y-mAbs Therapeutics (Nasdaq: YMAB) announced a poster presentation at the AACR Annual Meeting 2022 in New Orleans, showcasing preclinical data on its GD2 SADA construct. The SADA technology, licensed from Memorial Sloan Kettering and MIT, enhances tumor antigen binding and anti-tumor responses. Y-mAbs is focused on antibody-based cancer therapies and has one FDA-approved product, DANYELZA, aimed at GD2-expressing tumors, and another candidate, omburtamab, targeting B7-H3-expressing tumors.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has resubmitted its Biologics License Application (BLA) for 131I-omburtamab to the FDA as of March 31, 2022. This investigational monoclonal antibody targets B7-H3 in pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The submission is informed by pivotal Phase 2 study results, expected to be published later this year. Y-mAbs aims to meet a critical medical need, as there are currently no effective treatments beyond surgery and radiotherapy for these patients.